Sagent Pharmaceuticals Sets Date and Time for Release of First Quarter 2015 Results
April 27, 2015 16:15 ET
|
Sagent Pharmaceuticals, Inc.
SCHAUMBURG, Ill., April 27, 2015 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced...
Sagent Pharmaceuticals Appoints Michael Logerfo as President
April 16, 2015 07:30 ET
|
Sagent Pharmaceuticals, Inc.
SCHAUMBURG, Ill., April 16, 2015 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today...
Shlomo Yanai Joins Sagent Pharmaceuticals Board of Directors
April 16, 2015 07:30 ET
|
Sagent Pharmaceuticals, Inc.
SCHAUMBURG, Ill., April 16, 2015 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today...
Sagent Pharmaceuticals Announces the Launch of Vancomycin Hydrochloride for Injection, USP
April 13, 2015 06:00 ET
|
Sagent Pharmaceuticals, Inc.
SCHAUMBURG, Ill., April 13, 2015 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of Vancomycin Hydrochloride for Injection, USP, an anti-infective, in a 10...
Sagent Pharmaceuticals Announces Leadership Changes
March 26, 2015 07:30 ET
|
Sagent Pharmaceuticals, Inc.
--Jeffrey Yordon Retires as Chairman and CEO;
Board Member, Frank Kung, Ph.D. Appointed Chairman--
--Board Launches Search for Permanent CEO--
--Company Reiterates its Guidance Range for...
Sagent Pharmaceuticals Initiates a Nationwide Voluntary Recall of Atracurium Besylate Injection, USP, 50mg/5mL and 100mg/10mL Due to FDA Observations Pertaining to Aseptic and GMP Practices at the Manufacturer's Site Potentially Impacting Product Sterility
February 23, 2015 11:18 ET
|
Sagent Pharmaceuticals, Inc.
SCHAUMBURG, Ill., Feb. 23, 2015 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. today announced the voluntary nationwide recall of two lots of Atracurium Besylate Injection, USP, 50mg/5mL single-dose...
Sagent Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Results
February 19, 2015 07:00 ET
|
Sagent Pharmaceuticals, Inc.
Record quarterly revenue primarily driven by new product launches and Oct. 1 addition of Omega Laboratories
Full year results exceed updated Fiscal Year 2014 earnings guidance
SCHAUMBURG,...
Sagent Pharmaceuticals Sets Date and Time for Release of Fourth Quarter and Full Year 2014 Financial Results
February 12, 2015 08:00 ET
|
Sagent Pharmaceuticals, Inc.
SCHAUMBURG, Ill., Feb. 12, 2015 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced...
Sagent Pharmaceuticals to Present at 33rd Annual J.P. Morgan Healthcare Conference
January 08, 2015 16:29 ET
|
Sagent Pharmaceuticals, Inc.
SCHAUMBURG, Ill., Jan. 8, 2015 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced...
Sagent Pharmaceuticals Announces the Launch of Colistimethate for Injection, USP
December 30, 2014 08:30 ET
|
Sagent Pharmaceuticals, Inc.
SCHAUMBURG, Ill., Dec. 30, 2014 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of Colistimethate for Injection, USP, an anti-infective, in a...